Efficacy and Clinical Outcomes of Levosimendan in E-CPR

Recruiting

• Conditions: Cardiogenic Shock; Extracorporeal Membrane Oxygenation Complication

• Registration Number: NCT05730907
• Lead Sponsor: Hamad Medical Corporation

Brief Summary

Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation. Literature has demonstrated that ECMO initiated during advanced cardiopulmonary life support may confer superior survival rates with acceptable survival and a relatively low incidence of significant neurologic impairment. Levosimendan has not been investigated in patients with cardiac arrest who underwent Extracorporeal CPR (E-CPR). The current study aims to examine whether levosimendan use in the aforementioned patient population could improve survival and ECMO parameters.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-11
• Study First Submitted: 2022-12-05
• Study First Submitted QC: 2023-02-15
• Last Update Submitted: 2023-02-15
• Study First Posted: 2023-02-16
• Last Update Posted: 2023-02-16
• Study Start: 2023-02-20
• Primary Completion: 2023-04-30
• Study Completion: 2023-04-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival to hospital discharge	6 months	Survival to hospital discharge with good neurological outcomes

Secondary Outcome Measures

Name	Time	Method
Survival to decannulation	6 months	Survival to decannulation with good neurological outcomes
long term survival	6 months	long term survival

Trial Locations

Locations (1)

Hamad medical corporation; 🇶🇦 Doha, DA, Qatar